oral, brain-penetrant, reversible MAGL inh.

in vivo PK/PD in CNS (0.3-10 mpk PO)

from HTS and SBDD

Journal of Medicinal Chemistry

Takeda, Fujisawa, Japan

Compound 4f

The Takeda MAGL inhibitor, “compound 4f”, was selected by reviewer Joachim Rudolph. “MAGL (monoacylglycerol lipase) is implicated in neuroinflammation, and inhibitors of this enzyme are of interest as therapeutics in neurodegenerative…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: